secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001193125-24-214241
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio shareholders approve 85M share conversion; CEO Hung named Board Chair
--------------------------------------------------------------------------------

- Shareholders approved conversion of Series A Preferred into up to 85,120,200 Class A shares; conversion completed Sept 4, resulting in 333.8M Class A shares outstanding.
- CEO David Hung appointed Chair of the Board; Robert Bazemore appointed Lead Independent Director.
- Committee chairs set: Falberg (Audit), Vernon (Compensation), Bazemore (Nominating/Governance).
- All five proposals passed: directors elected, KPMG ratified, executive compensation approved, conversion approved, adjournment approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524214241/0001193125-24-214241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524214241/d888247d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-214241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer